Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

NEXT STORY
BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
PREV STORY
Novartis Cosentyx® shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara®*
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

author_avatar
NASDAQ Market News

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea

author_avatar
NASDAQ Market News